{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:07Z","timestamp":1781258947754,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20K10480"],"award-info":[{"award-number":["20K10480"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ek0410086h0001"],"award-info":[{"award-number":["21ek0410086h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Infection is one of the primary concerns during treatment for rheumatoid arthritis (RA) in elderly patients. However, infection risk of patients with RA receiving targeted therapy (TT) including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKIs) in elderly patients are scarce. The aim of this study was to compare the risk of hospitalized infection (HI) with TT versus methotrexate (MTX) therapy among young, elderly, and older elderly patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Japanese claims data, patients satisfying the following criteria were enrolled: (1) \u2265 one ICD10 code for RA; (2) \u2265 one prescription of MTX or TT (bDMARDs and JAKIs) between April 2008 and September 2018; and (3) \u226516 years old. We calculated the incidence rate (IR) of HI per 100 patient-years in the young, elderly, and older elderly groups (those aged 16\u201364, 65\u201374, and \u226575 years, respectively) and the IR ratio (TT vs. MTX) of HI. A logistic regression model was used to estimate the associations between HI and TT versus MTX in each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall IR of HI per 100 patient-years (95% confidence interval) was 3.2 [2.9\u20133.5], 5.0 [4.6\u20135.4], and 10.1 [9.5\u201310.9] in the young, elderly, and older elderly groups, respectively. Concomitant use of MTX or immunosuppressive DMARDs with TT was less frequent in the elderly and older elderly groups. The adjusted odds ratio of TT vs. MTX for HI was 1.3 (1.0\u20131.7;<jats:italic>p<\/jats:italic>= 0.021), 0.79 (0.61\u20131.0;<jats:italic>p<\/jats:italic>= 0.084), and 0.73 (0.56\u20130.94;<jats:italic>p<\/jats:italic>= 0.015) in the young, elderly, and older elderly groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The overall IR of HI was increased with age. The risk of HI under TT compared to MTX was not elevated in elderly and older elderly patients after adjusting for patients\u2019 characteristics and concomitant treatments.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-022-02807-9","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T07:02:30Z","timestamp":1654844550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Ryoko","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Majima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2807_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/art.38306","volume":"66","author":"J Widdifield","year":"2014","unstructured":"Widdifield J, Paterson JM, Bernatsky S, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheumatol. 2014;66:786\u201393.","journal-title":"Arthritis Rheumatol"},{"key":"2807_CR2","first-page":"2132","volume":"33","author":"O Kaipiainen-Seppanen","year":"2006","unstructured":"Kaipiainen-Seppanen O, Kautiainen H. Declining trend in the incidence of rheumatoid factor-positive rheumatoid arthritis in Finland 1980-2000. J Rheumatol. 2006;33:2132\u20138.","journal-title":"J Rheumatol"},{"key":"2807_CR3","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","volume":"62","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62:1576\u201382.","journal-title":"Arthritis Rheum"},{"key":"2807_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633\u20139.","journal-title":"Arthritis Rheum"},{"key":"2807_CR5","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis. 2020;23:1676\u201384.","journal-title":"Int J Rheum Dis"},{"key":"2807_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/1756-185X.12861","volume":"20","author":"TC Tan","year":"2017","unstructured":"Tan TC, Gao X, Thong BY, et al. Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis. 2017;20:737\u201345.","journal-title":"Int J Rheum Dis"},{"key":"2807_CR7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","volume":"64","author":"R Sakai","year":"2012","unstructured":"Sakai R, Komano Y, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res. 2012;64:1125\u201334.","journal-title":"Arthritis Care Res"},{"key":"2807_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/acr.21812","volume":"65","author":"J Widdifield","year":"2013","unstructured":"Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65:353\u201361.","journal-title":"Arthritis Care Res"},{"key":"2807_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628\u201334.","journal-title":"Arthritis Rheum"},{"key":"2807_CR10","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294\u2013300.","journal-title":"Arthritis Rheum"},{"key":"2807_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380\u20136.","journal-title":"Ann Rheum Dis"},{"key":"2807_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.22504","volume":"56","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:1125\u201333.","journal-title":"Arthritis Rheum"},{"key":"2807_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914\u201320.","journal-title":"Ann Rheum Dis"},{"key":"2807_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58:1755\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"2807_CR15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","volume":"59","author":"K Bechman","year":"2020","unstructured":"Bechman K, Oke A, Yates M, et al. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford, England). 2020;59:2563\u201371.","journal-title":"Rheumatology (Oxford, England)"},{"key":"2807_CR16","first-page":"29","volume":"36","author":"L Leon","year":"2018","unstructured":"Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018;36:29\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"2807_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","volume":"48","author":"DS Dalal","year":"2019","unstructured":"Dalal DS, Duran J, Brar T, et al. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to young: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;48:799\u2013807.","journal-title":"Semin Arthritis Rheum"},{"key":"2807_CR18","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/1756-185X.13662","volume":"22","author":"R Sakai","year":"2019","unstructured":"Sakai R, Tanaka E, Nishina H, Suzuki M, Yamanaka H, Harigai M. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database. Int J Rheum Dis. 2019;22:1978\u201384.","journal-title":"Int J Rheum Dis"},{"key":"2807_CR19","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1177\/0961203320952853","volume":"29","author":"R Sakai","year":"2020","unstructured":"Sakai R, Honda S, Tanaka E, et al. The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine. Lupus. 2020;29:1712\u20138.","journal-title":"Lupus."},{"key":"2807_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12891-021-04259-9","volume":"22","author":"K Kubota","year":"2021","unstructured":"Kubota K, Yoshizawa M, Takahashi S, Fujimura Y, Nomura H, Kohsaka H. The validity of the claims-based definition of rheumatoid arthritis evaluated in 64 hospitals in Japan. BMC Musculoskelet Disord. 2021;22:373.","journal-title":"BMC Musculoskelet Disord"},{"key":"2807_CR21","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3899\/jrheum.160012","volume":"43","author":"A Murota","year":"2016","unstructured":"Murota A, Kaneko Y, Yamaoka K, Takeuchi T. Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol. 2016;43:1984\u20138.","journal-title":"J Rheumatol"},{"key":"2807_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/art.39399","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol. 2016;68:56\u201366.","journal-title":"Arthritis Rheumatol"},{"key":"2807_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"2807_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-016-3631-z","volume":"37","author":"H Kawashima","year":"2017","unstructured":"Kawashima H, Kagami SI, Kashiwakuma D, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37:369\u201376.","journal-title":"Rheumatol Int"},{"key":"2807_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"2807_CR26","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754\u201364.","journal-title":"Arthritis Rheum"},{"key":"2807_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10067-016-3201-5","volume":"35","author":"T Kojima","year":"2016","unstructured":"Kojima T, Takahashi N, Funahashi K, et al. Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study. Clin Rheumatol. 2016;35:863\u201371.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2807_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"2807_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785\u201391.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02807-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02807-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T22:43:18Z","timestamp":1700692998000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02807-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2807"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02807-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"4 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Informed consent was not applicable for this study, based on the ethical guidelines for medical and health research involving human subjects issued by the Ministry of Health, Labor and Welfare and Ministry of Education, Culture, Sports, Science and Technology of Japan (revised on February 28, 2017). This study was approved by the ethics committee of Tokyo Women\u2019s Medical University (approval number: 4910).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tokyo Women\u2019s Medical University (TWMU), particularly the Division of Multidisciplinary Management of Rheumatic Diseases, Department of Rheumatology, has received unrestricted research grants from the following companies: Ayumi Pharmaceutical Co.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Nippon Kayaku Co., Ltd.; Taisho Toyama Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; and Teijin Pharma Ltd., with which TWMU paid the salaries of RS.MH has received research grants from the following companies: AbbVie Japan GK; Asahi Kasei Corp.; Astellas Pharma Inc.; Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co.; Daiichi-Sankyo, Inc.; Eisai Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Nippon Kayaku Co., Ltd.; Sekisui Medical; Shionogi & Co., Ltd.; Taisho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. MH has received speaker fees from the following companies: AbbVie Japan GK Ayumi Pharmaceutical Co.; Boehringer-Ingelheim Japan, Inc.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Kissei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma.ET has received lecture\/consulting fees from the following: Abbvie; Asahi Kasei Pharma Co.; Astellas Pharmaceutical; Ayumi Pharmaceutical; Chugai Pharmaceutical; Eisai Pharmaceutical; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Kyowa Pharma Chemical Co., Ltd.; Janssen Pharmaceutical K.K.; Mochida Pharmaceutical Co., Ltd.; Pfizer, Takeda Pharmaceutical; and Teijin Pharma Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}